Literature DB >> 20396416

Is statin therapy safe in patients with HIV/hepatitis C coinfection?

Jeffrey S Stroup1, Bryan Harris.   

Abstract

Statins are effective therapy for hypercholesterolemia and are commonly indicated in patients with HIV and hepatitis C virus infections. Unfortunately, in patients coinfected with these viruses, the safety of statins has not been conclusively evaluated. We retrospectively evaluated five coinfected patients in our outpatient clinic who received statin therapy. Although the sample size was small, we found that statins were safe in this population and recommend that further evaluation with a prospective controlled trial be undertaken to definitively answer this safety issue.

Entities:  

Year:  2010        PMID: 20396416      PMCID: PMC2848083          DOI: 10.1080/08998280.2010.11928595

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  20 in total

1.  Experience with statin use in patients with chronic hepatitis C infection.

Authors:  Kimberly Gibson; Joseph P Rindone
Journal:  Am J Cardiol       Date:  2005-09-08       Impact factor: 2.778

2.  Different anti-HCV profiles of statins and their potential for combination therapy with interferon.

Authors:  Masanori Ikeda; Ken-ichi Abe; Masashi Yamada; Hiromichi Dansako; Kazuhito Naka; Nobuyuki Kato
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

3.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

4.  Incidence of statin hepatotoxicity in patients with hepatitis C.

Authors:  Shirin Khorashadi; Noelle K Hasson; Ramsey C Cheung
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05-11       Impact factor: 11.382

5.  Lipid abnormalities in HIV/hepatitis C virus-coinfected patients.

Authors:  R Bedimo; R Ghurani; M Nsuami; D Turner; M-B Kvanli; G Brown; D Margolis
Journal:  HIV Med       Date:  2006-11       Impact factor: 3.180

6.  Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

Authors:  Carl J Fichtenbaum; John G Gerber; Susan L Rosenkranz; Yoninah Segal; Judith A Aberg; Terrence Blaschke; Beverly Alston; Fang Fang; Bradley Kosel; Francesca Aweeka
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

7.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Authors:  Kenneth E Sherman; Susan D Rouster; Raymond T Chung; Natasa Rajicic
Journal:  Clin Infect Dis       Date:  2002-02-06       Impact factor: 9.079

8.  Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.

Authors:  A Benesic; M Zilly; F Kluge; B Weissbrich; R Winzer; H Klinker; P Langmann
Journal:  Infection       Date:  2004-08       Impact factor: 3.553

9.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

Authors:  Naga Chalasani; Hisham Aljadhey; Joe Kesterson; Michael D Murray; Stephen D Hall
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

10.  Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus.

Authors:  Marisel Segarra-Newnham; David Parra; Ellen M Martin-Cooper
Journal:  Pharmacotherapy       Date:  2007-06       Impact factor: 4.705

View more
  3 in total

1.  Withholding statins in patients with underlying liver disease: wise or unwise?

Authors:  Robert P Perrillo
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-04

2.  Low-Density Lipoprotein Cholesterol Levels and Statin Treatment by HIV Status Among Multicenter AIDS Cohort Study Men.

Authors:  Anne K Monroe; Wei Fu; Michelle N Zikusoka; Lisa P Jacobson; Mallory D Witt; Frank J Palella; Lawrence A Kingsley; Wendy S Post; Todd T Brown
Journal:  AIDS Res Hum Retroviruses       Date:  2015-03-09       Impact factor: 2.205

3.  Evaluation of Statin Eligibility, Prescribing Practices, and Therapeutic Responses Using ATP III, ACC/AHA, and NLA Dyslipidemia Treatment Guidelines in a Large Urban Cohort of HIV-Infected Outpatients.

Authors:  Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel
Journal:  AIDS Patient Care STDS       Date:  2018-02       Impact factor: 5.078

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.